Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04313023 · ClinicalTrials.gov registry record · Phase 2
The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
A Phase 2 study of COVID-19, sponsored by Pulmotect.
- Completed
- Registry status
- Phase 2
- Development phase
- 217
- Enrollment target
- 15
- Study locations
NCT04313023 is a Phase 2 study of COVID-19 that has completed, run by Pulmotect. The registered enrollment target is 217 participants, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 15 study locations across 6 states.
The verdict
NCT04313023, a Phase 2 study of COVID-19, has completed, sponsored by Pulmotect.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 217 participants
- Enrollment target
- 15
- Study locations
Study Summary
Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days. Subjects will be followed for the incidence and severity of COVID-19 over 28 days. Subjects will be tested for infection with SARS-CoV-2 at the beginning, middle and end of the study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG PUL-042 Inhalation Solution
Study Locations (15)
Florida
- Clinical Research of South Florida Alliance for Multispecialty Research - Coral Gables
- Invesclinic US LLC - Fort Lauderdale
- Luminous Cinical Research- South Florida Urgent Care - Miami
- Entrust Clinical Research - Miami
- DBC Research - Tamarac
- Affinity Clinical Research, LLC - Tampa
Texas
- Invesclinic US LLC - Edinburg
- MD Anderson Cancer Center - Houston
- Next Level Urgent Care - Houston
California
- University of California Irvine - Orange
- Premier Urgent Care of California - San Bernardino
Oklahoma
- Ascension St John - Bartlesville
- Ascension St. John - Tulsa
Georgia
- Clinical Research Atlanta - Stockbridge
Louisiana
- Willis-Knighton Physcian Network - Bossier City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 217 participants |
| Start Date | 2020-06-09 |
| Est. Completion | 2021-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04313023
The ClinicalTrials.gov registry entry for NCT04313023 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 217 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,213-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Pulmotect, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04313023 reports 15 study locations spanning 6 distinct geographic areas - top geographies include Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT04313023 about?
NCT04313023 is a clinical study titled "The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2". Subjects who have documented exposure to SARS-CoV-2 (COVID-19) will receive 4 doses of PUL-042 Inhalation Solution or 4 doses of a placebo solution by inhalation over 10 days. Subjects will be followed for the incidence and severity of COVID-19 over 28 days. Subjects will be tested for infection wit...
What is the current status of trial NCT04313023?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 217 participants. The study started on 2020-06-09. Estimated completion is 2021-07-31.
What conditions does trial NCT04313023 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04313023?
The interventions under investigation include: Placebo (DRUG), PUL-042 Inhalation Solution (DRUG).
Who is sponsoring clinical trial NCT04313023?
This trial is sponsored by Pulmotect, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04313023 being conducted?
This trial has 15 study locations across California, Florida, Georgia, Louisiana, Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Arginine Replacement Therapy in COVID-19
RECRUITING · Phase 2
-
A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children
RECRUITING · Phase 2
-
A Nasal Treatment for COVID-19
RECRUITING · Phase 2
-
Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults
RECRUITING · Phase 2
-
Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19
RECRUITING · Phase 2
-
Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.